Tagrisso-chemotherapy, phase 3 unbreakable, ‘climax’ with Dato-DXd product approval data released Tagrisso, NCCN category 1 designation for ‘significant’ anti-cancer combination therapy Emphasis on “proving an overwhelming therapeutic effect in patients with an EGFR mutation only” On the 19th, AstraZeneca (hereinafter referred to as AZ) distributed three consecutive press releases at the headquarters level summarizing the … Continue reading AstraZeneca’s Tagrisso and Dato-DXd Achievements in Lung Cancer Treatment